Centessa Pharmaceuticals PLC
CNTA16.400USD
-0.410-2.44%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.19BValor de mercado
PerdaP/L TTM
Mais detalhes de Centessa Pharmaceuticals PLC Empresa
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
Informações da empresa
Código da empresaCNTA
Nome da EmpresaCentessa Pharmaceuticals PLC
Data de listagemMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Número de funcionários77
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 28
Endereço3rd Floor
CidadeALTRINCHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited Kingdom
Código postalWA14 2DT
Telefone447391789784
Sitehttps://www.centessa.com/
Código da empresaCNTA
Data de listagemMay 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
Investidores
Investidores
Proporção
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
Tipos de investidores
Investidores
Proporção
Hedge Fund
23.53%
Venture Capital
23.05%
Investment Advisor
19.40%
Investment Advisor/Hedge Fund
15.34%
Private Equity
10.46%
Research Firm
2.54%
Individual Investor
0.50%
Endowment Fund
0.06%
Other
5.12%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
220
133.64M
100.03%
-11.01M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
SPDR S&P International Small Cap ETF
0.09%
iShares Biotechnology ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.98%
ProShares Ultra Nasdaq Biotechnology
Proporção0.14%
Invesco Nasdaq Biotechnology ETF
Proporção0.14%
SPDR S&P International Small Cap ETF
Proporção0.09%
iShares Biotechnology ETF
Proporção0.07%
T Rowe Price Small-Mid Cap ETF
Proporção0.05%
Fidelity Nasdaq Composite Index ETF
Proporção0%
First Trust IPOX Europe Equity Opportunities ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
